Akari Therapeutics (AKTX) Net Cash Flow (2014 - 2026)

Akari Therapeutics (AKTX) has 9 years of Net Cash Flow data on file, last reported at -$2.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 14223.53% year-over-year to -$2.4 million; the trailing twelve-month figure through Mar 2026 stood at $185000.0 (down 80.51% YoY), and the FY2025 full-year result was $2.6 million, up 320.22% from the prior year.
• Net Cash Flow slipped to -$2.4 million in Q1 2026, from $2.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $2.9 million in Q2 2024 to a low of -$4.4 million in Q2 2023.
• A 4-year average of -$831384.6 and a median of -$892000.0 in 2023 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow soared 8963.33% in 2025 and plunged 14223.53% in 2026, its largest moves.
• Tracing AKTX's Net Cash Flow over 4 years: stood at -$892000.0 in 2023, then jumped by 103.36% to $30000.0 in 2024, then soared by 8963.33% to $2.7 million in 2025, then tumbled by 189.55% to -$2.4 million in 2026.
• Business Quant data shows AKTX's Net Cash Flow at -$2.4 million in Q1 2026, $2.7 million in Q4 2025, and -$224000.0 in Q3 2025.